Study of the effect of metformin along with pumega5 in patients with PCOS

Study of the effect of metformin along with pumega5 on the ZnF12 and TSP1 pathway and investigating the expression of UTS2 and it’s receptor, G6PD, ALDOA in follicular fluid and blood samples in patients with PCOS

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250830067049N1

Enrollment

Registered

2025-10-01

Start date

2025-10-04

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome disease. Polycystic ovarian syndrome

Interventions

Intervention 1: Control group: Patients with PCOS and no treatment. Intervention 2: Intervention group1: Patients with PCOS and taking metformin. Intervention 3: Intervention group 2 : Patients with P

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with polycystic ovary syndrome (PCOS) Age 18 to 40 years old Antral follicle count (AFC) above 20 AMH>3.36 mg/ml BMI <30 kg/m2) Ovarian stimulation treatment cycles with antagonist only

Exclusion criteria

Exclusion criteria: Endometriosis Decreased ovarian reserve Chromosomal abnormality History of allergy to Metformin and Pumega 5 drugs

Design outcomes

Primary

Measure	Time frame
Ultrasound view of polycystic ovary. Timepoint: 3 monthsBefore the study and 3 months after taking the drug. Method of measurement: Sonography.;Enlargement of the ovaries. Timepoint: Before the study and 3 months after taking the drug. Method of measurement: Sonography.;Ultrasound image showing or not seeing ascetic fluid inside the abdomen. Timepoint: Before the study and 3 months after taking the drug. Method of measurement: Sonography.	—

Measure

Time frame

Ultrasound view of polycystic ovary. Timepoint: 3 monthsBefore the study and 3 months after taking the drug. Method of measurement: Sonography.;Enlargement of the ovaries. Timepoint: Before the study and 3 months after taking the drug. Method of measurement: Sonography.;Ultrasound image showing or not seeing ascetic fluid inside the abdomen. Timepoint: Before the study and 3 months after taking the drug. Method of measurement: Sonography.

—

Secondary

Measure	Time frame
Determining the reduction in the levels of the aforementioned proteins in serum before and after the intervention in all patients. Timepoint: Before the study and 3 months after the study. Method of measurement: Real-time qPCR test.;Determining the reduction in the amount of the aforementioned proteins in the follicular fluid before intervention in all patients. Timepoint: Before the study. Method of measurement: Real time qPCR test.;Determining the reduction in the expression of TSP1, ZnF12, G6PD, ALDOA, UTS2 genes and their receptor in the blood after intervention in all patients. Timepoint: 3 months after taking the drug. Method of measurement: ELISA test.	—

Measure

Time frame

Determining the reduction in the levels of the aforementioned proteins in serum before and after the intervention in all patients. Timepoint: Before the study and 3 months after the study. Method of measurement: Real-time qPCR test.;Determining the reduction in the amount of the aforementioned proteins in the follicular fluid before intervention in all patients. Timepoint: Before the study. Method of measurement: Real time qPCR test.;Determining the reduction in the expression of TSP1, ZnF12, G6PD, ALDOA, UTS2 genes and their receptor in the blood after intervention in all patients. Timepoint: 3 months after taking the drug. Method of measurement: ELISA test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamaneh Tohidi

Islamic Azad University

samaneh.tohidi88@gmail.com+98 21 7749 1872

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026